10.27
Ginkgo Bioworks Holdings Inc stock is traded at $10.27, with a volume of 3.55M.
It is down -12.67% in the last 24 hours and up +45.47% over the past month.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
See More
Previous Close:
$11.76
Open:
$11.62
24h Volume:
3.55M
Relative Volume:
0.75
Market Cap:
$691.58M
Revenue:
$141.31M
Net Income/Loss:
$-297.87M
P/E Ratio:
-1.9042
EPS:
-5.3933
Net Cash Flow:
$-168.20M
1W Performance:
-21.00%
1M Performance:
+45.47%
6M Performance:
+29.18%
1Y Performance:
-32.08%
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Name
Ginkgo Bioworks Holdings Inc
Sector
Industry
Phone
(877) 442-5362
Address
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
DNA
Ginkgo Bioworks Holdings Inc
|
10.27 | 691.58M | 141.31M | -297.87M | -168.20M | -5.3933 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-26 | Downgrade | TD Cowen | Buy → Hold |
| May-15-24 | Downgrade | BTIG Research | Neutral → Sell |
| May-10-24 | Downgrade | William Blair | Mkt Perform → Underperform |
| Nov-14-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-09-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-02-23 | Downgrade | Goldman | Neutral → Sell |
| May-11-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-29-22 | Initiated | Berenberg | Buy |
| Oct-04-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Feb-23-22 | Initiated | Goldman | Neutral |
| Feb-01-22 | Initiated | BofA Securities | Neutral |
| Jan-28-22 | Initiated | BofA Securities | Buy |
| Jan-07-22 | Initiated | BTIG Research | Buy |
| Nov-29-21 | Initiated | Jefferies | Buy |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Oct-12-21 | Initiated | William Blair | Outperform |
| Sep-20-21 | Initiated | HSBC Securities | Buy |
View All
Ginkgo Bioworks Holdings Inc Stock (DNA) Latest News
Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand - Yahoo Finance
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market - Zacks Investment Research
Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market - Yahoo Finance
Ginkgo Bioworks Holdings Inc (DNA) PT Raised to $11 at TD Cowen - StreetInsider
Ginkgo Bioworks Holdings (NYSE:DNA) Stock Forecast & Analyst Predictions - Simply Wall Street
Form 144 Ginkgo Bioworks Holdings For: 12 October By Investing.com - Investing.com South Africa
DNA Surges As Ginkgo Bioworks Lands Key AI Drug Deals - Timothy Sykes
What's Going on With Ginkgo Bioworks Stock on Friday? - Benzinga
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science Program - www.marketscreener.com
Ginkgo Bioworks Provides Autonomous Lab Access To National Science Foundation X-Labs Researchers, Contributing Cloud Lab Time And Protein Testing Services To $1.5 Billion Breakthrough Science Program - www.marketscreener.com
Researchers in a $1.5 billion science initiative will be able to use a robot lab remotely. - Stock Titan
Ginkgo Bioworks, Araceli Biosciences Add Cellular Imaging to Autonomous Lab - www.marketscreener.com
Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop - Financial Times
Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock - Investing.com
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Zacks Investment Research
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Ginkgo Bioworks CFO Steven Coen Sells 2,403 Shares Under Rule 10b5-1 Plan on October 5, 2026 - Kalkine Media
A planned share sale leaves Ginkgo Bioworks (DNA) CFO holding 49,448 shares directly. - Stock Titan
Ginkgo Bioworks: The Valuation Has Outrun The Business (NYSE:DNA) - Seeking Alpha
Officer Steven P. Coen proposes selling 2,403 Ginkgo Bioworks (NYSE: DNA) shares. - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Ginkgo Bioworks: Another Curious Rally (NYSE:DNA) - Seeking Alpha
AbbVie and Takeda can use AI models without revealing sequences to other members - Stock Titan
Ginkgo Bioworks (DNA) Slips 1.88% to $10.46, Testing the Middle of a Well-Defined RangeWide Range Bar - siam.in
(DNA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors - GlobeNewswire Inc.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - finance.yahoo.com
Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains? - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenges in the Biotech Sector - DirectorsTalk Interviews
Ginkgo Bioworks (DNA) officer may sell 2,200 shares - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Ginkgo Bioworks (NYSE: DNA) director sells 5,000 shares near $7.08 - Stock Titan
Ginkgo Bioworks And Eli Lilly And Company Enter Partnership To Integrate Ginkgo Datapoints With Lilly TuneLab - marketscreener.com
Director plans potential 5,000-share sale at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Up to $17.5M awarded to Ginkgo for medicines made for one patient - Stock Titan
Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines - Investing News Network
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com Australia
DNAGinkgo Bioworks Holdings Inc Earnings - Finviz
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com South Africa
BTIG cuts Ginkgo Bioworks stock price target on transition concerns By Investing.com - Investing.com Canada
BTIG cuts Ginkgo Bioworks stock price target on transition concerns - Investing.com
Ginkgo Bioworks Holdings Inc (DNA) PT Lowered to $5 at BTIG - StreetInsider
(DNA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5 - Moomoo
BTIG reiterates Ginkgo Bioworks stock Sell rating at $5 target By Investing.com - Investing.com Canada
BTIG reiterates Ginkgo Bioworks stock Sell rating at $5 target By Investing.com - Investing.com India
BTIG reiterates Ginkgo Bioworks stock Sell rating at $5 target By Investing.com - Investing.com Nigeria
BTIG reiterates Ginkgo Bioworks stock Sell rating at $5 target - investing.com
Ginkgo Bioworks Holdings Inc Stock (DNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ginkgo Bioworks Holdings Inc Stock (DNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coen Steven P. | Officer |
Oct 05 '26 |
Proposed Sale |
15.00 |
2,403 |
36,045 |
0 |
| Che Austin | Officer |
Sep 17 '26 |
Proposed Sale |
7.29 |
2,200 |
16,038 |
0 |
| HENRY CHRISTIAN O | Director |
Sep 15 '26 |
Proposed Sale |
7.08 |
5,000 |
35,406 |
0 |
| HENRY CHRISTIAN O | Director |
Sep 15 '26 |
Sale |
7.08 |
5,000 |
35,405 |
19,310 |
| Coen Steven P. | See remarks |
Aug 24 '26 |
Sale |
6.98 |
330 |
2,302 |
51,851 |
| Coen Steven P. | Officer |
Aug 24 '26 |
Proposed Sale |
6.98 |
330 |
2,302 |
0 |
| Che Austin | Officer |
Aug 17 '26 |
Proposed Sale |
6.66 |
2,200 |
14,652 |
0 |
| Coen Steven P. | Officer |
Jul 17 '26 |
Proposed Sale |
7.90 |
752 |
5,943 |
0 |
| Coen Steven P. | See remarks |
Jul 17 '26 |
Sale |
7.90 |
752 |
5,943 |
51,438 |
| Che Austin | Officer |
Jun 10 '26 |
Proposed Sale |
8.06 |
2,200 |
17,732 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):